ClinicalTrials.gg
RecruitingNCT05291676Updated Nov 10, 2026

Systems Investigation of Vaccine Responses in Aging and Frailty

A Phase 2 interventional study of Fluzone and Fluad in Influenza, sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Yale University · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.
Updated Nov 10, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 966 studies in Influenza, Human with a site in United States — 60 open to participants now, 85 under way, 7 of them phase 3. Influenza, Human · United States.

Planned enrollment
579th of 843
96 · median 270
Started
2023
with 41 others
Phase 2
161 of 966
7 open now
Primary completion
2029-05
later than 77 of 83 live
Registered
793rd of 966
by date

Among the 966 studies in Influenza, Human with a site in United States, this one is the 579th largest by planned enrollment of the 843 interventional ones that give a count, is one of 42 that started in 2023, is one of 161 in phase 2, reaches primary completion later than 77 of the 83 other live ones, and was the 793rd registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

60 of the 966 studies in Influenza, Human with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 21 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 966 studies in Influenza, Human with a site in United States, or all of them as a file.
02

Study summary

This study will compare the immune response signatures (including immunologic, transcriptomic and metabolomic) of the two influenza vaccines approved for use in adults age 65 and over (Fluad and Fluzone High-Dose).

Read the detailed description

There are two vaccines currently approved for use in adults age 65 and greater: a high-dose (HD) influenza vaccine (Fluzone High-Dose) that contains 4 times the hemagglutinin dose found in the standard vaccine, and a standard-dose (SD) vaccine containing the proprietary MF59 adjuvant (Fluad). Both vaccines give significantly highly antibody responses to influenza in older adults. This study will directly compare the HD and SD vaccines in nursing home residents, the population of older adults most vulnerable to influenza outbreaks and morbidity and mortality. It will comprehensively study the innate and adaptive response to vaccination, as well as elucidate transcriptomic and proteomic signatures of vaccine response.

This is a randomized, open label study comparing the two vaccines currently approved for use in adults age ≥ 65 years: the high-dose influenza vaccine and the MF59 adjuvanted standard-dose vaccine, both quadrivalent. The young group will be comprised of individuals 21-30 years of age, and the older cohorts will consist of nursing home residents ≥65 years. Participants will also be evaluated for evidence of influenza-like illness (ILI). ILI is defined to include clinical presentation in older adults: by the presence of either two respiratory symptoms (cough, sore throat, shortness of breath, and nasal stuffiness) or one respiratory and one systemic symptom (headache, malaise, temperature >99° F, report of feverishness and muscle aches, or altered mental status). Diagnoses of influenza will be confirmed using a real-time polymerase chain reaction (PCR) test on a nasopharyngeal (NP) swab specimen done by the hospital Virology Laboratory and facilitated by the participating medical directors.

Although this is neither an efficacy or effectiveness study, participants will be randomized 1:1 to either the high-dose influenza vaccine or the MF59 vaccine within age strata. This will ensure a non-biased allocation of the two vaccines and attempts to balance participant characteristics within age strata.

03

Conditions studied

  • Influenza

Browse trials for

Keywords

  • vaccine
  • influenza vaccine
  • older adults
  • vaccine response
  • toll-like receptors
  • immune response
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 21-40 or 65 and older
  • Ability to understand and give (surrogate consent may apply to nursing home subjects who are decisionally impaired, with verbal assent to be obtained from subject)
  • Plan to be in the New Haven, CT area for the next 4-6 weeks

Exclusion criteria

Exclusion Criteria:

  • Current use of medication, such as antibiotics in past two weeks. To clarify, patients taking antibiotics for the reason of a current acute infection will not be eligible. Those potential participants receiving antibiotics for prophylaxis purposes will be eligible to participate. The intention is not to create a separate group to drawn conclusions, but not to exclude these participants who are not acutely ill.
  • Evidence of acute infection, identified by self- report of fever or symptoms in past two weeks
  • Treatment for cancer in past three months.
  • Previous adverse reaction to influenza vaccine requiring medical attention, such as allergic response (rash, anaphylaxis) or Guillain-Barré syndrome.
  • Pregnant/possibly pregnant.
  • History of organ, bone marrow or stem cell transplant, liver cirrhosis, kidney disease requiring dialysis, /AIDS, or active
  • Blood donation of 1 pint or more in past 2 months
  • Treatment with clinical trial medication
  • Presence of any other condition (e.g., geographical or social), actual or projected, that the investigator feels would restrict or limit the patient's participation for the duration of the study. This provision includes participants who have 50% or more missed appointments in the last three months.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Active comparator
    21-30 standard dose Fluad

    Participants age 21-30 years will receive the standard dose Fluad

    Biological: Fluad

  • Active comparator
    21-30 high dose Fluzone

    Participants age 21-30 years will receive the high dose Fluzone

    Biological: Fluzone

  • Experimental
    ≥65 years standard dose Fluad

    Participants age ≥65 years will receive standard dose Fluad

    Biological: Fluad

  • Experimental
    ≥65 years high dose Fluzone

    Participants age ≥65 years will receive high dose Fluzone

    Biological: Fluzone

Interventions

  • BiologicalFluzone

    Fluzone High-Dose 0.7 ml intramuscular injection, standard as recommended by manufacturer

  • BiologicalFluad

    Fluad Quadrivalent, MF59 adjuvanted 0.5 ml intramuscular injection, standard as recommended by manufacturer

06

What researchers measure

Primary outcomes

  1. Change in production of IL-6 in monocytes to assess innate immune inflammatory response

    Measurement of IL-6 production in monocytes via flow cytometry

    Time frame: Baseline and at Day 2, 7, and 28 post-vaccine

Secondary outcomes

  1. Change in Hemagglutination inhibition titer (HAI) in response to vaccination

    HAI titers levels in blood measured prior to and at day 28 post-vaccine

    Time frame: Baseline and Day 28

  2. Change in transcriptomic analyses of gene expression

    RNA-seq analysis of RNA derived from peripheral blood mononuclear cells (PBMCs) and platelet-rich plasma (PRP)

    Time frame: At Baseline, Day 2, Day 7, Day 28 and Day 70

  3. Change in proteomic analyses

    Analysis of protein expression using Mass Spectrometry in plasma

    Time frame: At Baseline, Day 2, Day 7, Day 28 and Day 70

  4. Number of participants with changes in innate immune function from PBMCs and PRP as assessed using flow cytometry

    Analyses will include intracellular production of cytokines including IL-10 and TNF-alpha in monocyte populations from PBMCs and expression of platelet activation markers such as CD63 and P-selectin on platelets. The effects of ex vivo Toll-like Receptor stimulation on these parameters will also be assessed.

    Time frame: At Baseline, Day 2, Day 7, Day 28 and Day 70

  5. Number of participants with changes in B and T cell function from PBMCs as assessed using flow cytometry

    This will include analysis of number and proportion of antibody-secreting cells post-vaccine, and analyses of T cells following ex vivo stimulation of PBMCs with influenza hemagglutinins.

    Time frame: At Baseline, Day 2, Day 7, Day 28 and Day 70

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data with Protected Health Information (PHI) removed on participant demographics and health conditions, and primary and secondary outcome data will be uploaded to the NIH ImmPort as required by the NIH Human Immunology Project Consortium. Publicly available data will be released after publication. Registration on ImmPort required by the NIH. Timeframe for data upload will be approximately 6-12 months after each influenza vaccine season during the study.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for May 2029, 66 months after the start.

Of 36 non-industry phase 2 interventional studies under Influenza, Human, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 56. This study's planned 66 months is above that.

Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Apr 2027 → May 2029 and completion Apr 2027 → May 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2022
First posted
Mar 23, 2022
StartActual
Nov 6, 2023
Primary completionEst.
May 2029was Apr 2027
CompletionEst.
May 2029was Apr 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 2027→May 2029
Nov 10, 2026
Study completion
Apr 2027→May 2029
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Apr 2027→May 2029
    Study completion Apr 2027→May 2029
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05291676
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Mar 23, 2022
Start date
Nov 6, 2023
Primary completion
May 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Irene Matos, RN
Contact
irene.matos@yale.edu
(203) 737-4739
Albert Shaw, MD, PhD
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion